ORYZON to Provide Corporate Progress Updates at Several Events in May-June

Foro MedCap 2025BIO International Convention 2025 Discovery and Development Europe 2025 MADRID and CAMBRIDGE, Mass., May 27, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and a European leader in epigenetics, announced today that its management will give an update on corporate progress at several international events in May-June. Oryzon will attend the Foro Medcap 2025, which will take place at the Madrid Stock Exchange palace in Ma ...